Engineered immune cells take aim at blistering skin disease
NCT ID NCT07681388
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This study investigates whether a single infusion of a patient's own genetically modified immune cells (CD19 CAR-T cells) can safely control moderate-to-severe pemphigus vulgaris that hasn't responded to standard treatments. The therapy targets and depletes B cells, which are thought to drive the disease. Three adults with refractory pemphigus vulgaris will receive the treatment after chemotherapy, and researchers will monitor side effects and changes in skin blistering over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CD19 CAR-T cells
What this could lead to
If successful, this could offer a new treatment option for people with hard-to-control pemphigus vulgaris, potentially reducing symptoms and need for ongoing medication.
What could go wrong
This is a very early, small study with only 3 participants, so results may not apply broadly. CAR-T therapy carries risks like cytokine release syndrome and infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PEMPHIGUS VULGARIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- COVID-19 Booster Study for Autoimmune Patients (NCT05000216)
- Clobetasol & Laser for Pemphigus Oral Lesions NCT07641725
- Blood Clot Study in Autoimmune Skin Disease | NCT06037187
- Autoimmune Blistering Disease Study | NCT02753777
- Rituximab Doses for Pemphigus – NCT07457944
- Topical Insulin for Pemphigus Lesions (NCT07461103)
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Traditional Chinese and Western Medicine Hospital of Wuhan, Wuhan, Hubei
RECRUITINGWuhan, Hubei, China
Contact Phone: •••-•••-•••• Email: •••••@•••••